Cancer-related networks: A help to understand, predict and change malignant transformation

Seminars in Cancer Biology

Volumn 23, Issue 4, 2013, Pages 209-212

  Csermely, Peter ^a   Korcsmáros, Tamás ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Anti cancer therapies; Autophagy; Cancer attractors; Cancer stem cells; Game theory; Inflammation; Interactome; Metabolic modeling; Networks; Protein kinase inhibitors; Signaling.

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL POPULATION; DRUG DESIGN; DRUG TARGETING; EDITORIAL; GAME; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN STRUCTURE; PUBLICATION; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84881109934     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.06.011     Document Type: Editorial

References (44)

1. Dulbecco R. Cancer progression: the ultimate challenge. International Journal of Cancer 1989, 44:S6-S9.
2. Hornberg J.J., Bruggeman F.J., Westerhoff H.V., Lankelma J. Cancer: a systems biology disease. BioSystems 2006, 83:81-90.
3. Csermely P., Korcsmaros T., Kiss H.J.M., London G., Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. A comprehensive review. Pharmacology & Therapeutics 2013, 138:333-408.
4. Klinke D.J. Signal transduction networks in cancer: quantitative parameters influence network topology. Cancer Research 2010, 70:1773-1782.
5. Pe'er D., Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011, 144:864-873.
6. Sharma S.V., Haber D.A., Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Reviews Cancer 2010, 10:241-253.
7. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
8. Berger S.I., Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009, 25:2466-2472.
9. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Current Cancer Drug Targets 2009, 9:307-319.
10. Azmi A.S., Wang Z., Philip P.A., Mohammad R.M., Sarkar F.H. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Molecular Cancer Therapeutics 2010, 9:3137-3144.
11. Glaser B. Genetic analysis of complex disease-a roadmap to understanding or a colossal waste of money. Pediatric Endocrinology Reviews 2010, 7:258-265.
12. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
13. Vazquez A. Optimal drug combinations and minimal hitting sets. BMC Systems Biology 2009, 3:81.
14. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine 2013, 19:619-625.
15. Pritchard J.R., Bruno P.M., Hemann M.T., Lauffenburger D.A. Predicting cancer drug mechanisms of action using molecular network signatures. Molecular BioSystems 2013, 9:1604-1619.
16. Pritchard J.R., Bruno P.M., Gilbert L.A., Capron K.L., Lauffenburger D.A., Hemann M.T. Defining principles of combination drug mechanisms of action. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:E170-E179.
17. Jiang H., Pritchard J.R., Williams R.T., Lauffenburger D.A., Hemann M.T. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nature Chemical Biology 2011, 7:92-100.
18. Jonsson P.F., Bates P.A. Global topological features of cancer proteins in the human interactome. Bioinformatics 2006, 22:2291-2297.
19. Cheng T.M., Gulati S., Agius R., Bates P.A. Understanding cancer mechanisms through network dynamics. Briefings in Functional Genomics 2012, 11:543-560.
20. Schramm G., Wiesberg S., Diessl N., Kranz A.L., Sagulenko V., Oswald M., et al. PathWave: discovering patterns of differentially regulated enzymes in metabolic pathways. Bioinformatics 2010, 26:1225-1231.
21. Schramm G., Surmann E.M., Wiesberg S., Oswald M., Reinelt G., Eils R., et al. Analyzing the regulation of metabolic pathways in human breast cancer. BMC Medical Genomics 2010, 3:39.
22. Kuzu G., Keskin O., Gursoy A., Nussinov R. Constructing structural networks of signaling pathways on the proteome scale. Current Opinion in Structural Biology 2012, 22:367-377.
23. Buch I., Fishelovitch D., London N., Raveh B., Wolfson H.J., Nussinov R. Allosteric regulation of glycogen synthase kinase 3?: a theoretical study. Biochemistry 2010, 49:10890-10901.
24. Keskin O., Nussinov R., Gursoy A. PRISM: protein-protein interaction prediction by structural matching. Methods in Molecular Biology 2008, 484:505-521.
25. Engin H.B., Gursoy A., Nussinov R., Keskin O. Network-based strategies can help mono- and poly-pharmacology drug discovery: a systems biology view. Current Pharmaceutical Design 2013, [in press]. 10.2174/13816128113199990066.
26. Vellai T., Bicsák B., Tóth M.L., Takács-Vellai K., Kovács A.L. Regulation of cell growth by autophagy. Autophagy 2008, 4:507-509.
27. Korcsmáros T., Farkas I.J., Szalay M.S., Rovó P., Fazekas D., Spiró Z., et al. Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery. Bioinformatics 2010, 26:2042-2050.
28. Fazekas D., Koltai M., Türei D., Módos D., Pálfy M., Dúl Z., et al. SignaLink 2-a signaling pathway resource with multi-layered regulatory networks. BMC Systems Biology 2013, 7:7.
29. Gáspár M.E., Csermely P. Rigidity and flexibility of biological networks. Briefings in Functional Genomics 2012, 11:443-456.
30. Gyurkó D., Söti C., Steták A., Csermely P. System level mechanisms of adaptation, learning, memory formation and evolvability: the role of chaperone and other networks. Current Protein & Peptide Science 2013, [in press]. arxiv:1206.0094.
31. Rajapakse I., Groudine M., Mesbahi M. Dynamics and control of state-dependent networks for probing genomic organization. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17257-17262.
32. Nussinov R., Tsai C.J., Csermely P. Allo-network drugs: harnessing allostery in cellular networks. Trends in Pharmacological Sciences 2011, 32:686-693.
33. Csermely P. Creative elements: network-based predictions of active centres in proteins and cellular and social networks. Trends in Biochemical Sciences 2008, 33:569-576.
34. Kauffman S. Homeostasis and differentiation in random genetic control networks. Nature 1969, 224:177-178.
35. Kauffman S. Differentiation of malignant to benign cells. Journal of Theoretical Biology 1971, 31:429-451.
36. Huang S., Ernberg I., Kauffman S. Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. Seminars in Cell & Developmental Biology 2009, 20:869-876.
37. Huang S. On the intrinsic inevitability of cancer: from foetal to fatal attraction. Seminars in Cancer Biology 2011, 21:183-199.
38. Li J., Lenferink A.E., Deng Y., Collins C., Cui Q., Purisima E.O., et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nature Communications 2010, 1:34.
39. Wang E. Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Letters 2013, [in press]. 10.1016/j.canlet.2012.11.050.
40. Flaberg E., Markasz L., Petranyi G., Stuber G., Dicso F., Alchihabi N., et al. High-throughput live-cell imaging reveals differential inhibition of tumor cell proliferation by human fibroblasts. International Journal of Cancer 2011, 128:2793-2802.
41. Flaberg E., Guven H., Savchenko A., Pavlova T., Kashuba V., Szekely L., et al. The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth. International Journal of Cancer 2012, 131:2274-2283.
42. Bozóky B., Savchenko A., Csermely P., Korcsmáros T., Dúl Z., Pontén F., et al. Novel signatures of cancer-associated fibroblasts. International Journal of Cancer 2013, 133:286-293.
43. Klein G. Evolutionary aspects of cancer resistance. Seminars in Cancer Biology 2013, [in press].
44. Cavaliere M., Sedwards S., Tarnita C.E., Nowak M.A., Csikász-Nagy A. Prosperity is associated with instability in dynamical networks. Journal of Theoretical Biology 2012, 299:126-138.